Cancer Research Tie-Up in Between Belgian's Ablynx and Merck

by Bidita Debnath on  February 3, 2014 at 10:44 PM General Health News
RSS Email Print This Page Comment
Font : A-A+

Belgian biotechnology company Ablynx said that it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros.
 Cancer Research Tie-Up in Between Belgian's Ablynx and Merck
Cancer Research Tie-Up in Between Belgian's Ablynx and Merck

The contract, to identify proteins which may lead to cancer immunotherapy treatments, involves an initial payment of 20 million euros plus 10.7 million euros for the three-year research programme.

Subsequent royalties on sales could lead to payment of 1.7 billion euros, Ablynx said in a statement.

Merck will be responsible for development, manufacture and say of any treatments generated by the research.

Immunotherapy treatments aim to boost the body's own immune response so as to fight cancer.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Top Ten Selling Drugs Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive